Dyspnea News and Research RSS Feed - Dyspnea News and Research

Dyspnea or dyspnoea or shortness of breath is a debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations.
Further Reading
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]
Internet-based physical activity can improve health-related quality of life in patients with COPD

Internet-based physical activity can improve health-related quality of life in patients with COPD

A pedometer-based walking program supported by Internet-based instruction and support can improve health-related quality of life (HRQOL) in patients with chronic obstructive pulmonary disease (COPD), according to a new study presented at the 2014 American Thoracic Society International Conference. [More]
Individuals with dyspnea have increased long-term mortality risk

Individuals with dyspnea have increased long-term mortality risk

Individuals with dyspnea, or shortness of breath, have an increased long-term mortality risk compared with individuals without dyspnea, according to a new study presented at the 2014 American Thoracic Society International Conference. [More]
UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. [More]
Low baseline QOL scores does not predict worse survival in patients undergoing lung cancer surgery

Low baseline QOL scores does not predict worse survival in patients undergoing lung cancer surgery

Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions. [More]
GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare today announced the first seven markets where Vizamyl (Flutemetamol F18 injection), a radioactive diagnostic agent approved by the FDA will be available. Late in the second quarter of 2014, Vizamyl will be available to imaging centers near East Rutherford, NJ, Woburn, MA, Beltsville, MD, East Lansing, MI, Dallas, TX, Phoenix, AZ and Colton, CA. [More]
FDA grants clearance for Breathe Technologies’ Non-Invasive Open Ventilation System

FDA grants clearance for Breathe Technologies’ Non-Invasive Open Ventilation System

Breathe Technologies, Inc. announced today that the U.S. Food and Drug Administration has granted the fifth 510(k) clearance for its Non-Invasive Open Ventilation System, allowing its use with compressed air supply for non-oxygen dependent patients. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]
STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully finished mesenchymal stem cell therapy for the pulmonary fibrosis patient who visited Korea from Calgary, Canada. [More]
Dyspnea during light daily activities used as indicator of exercise intolerance and low fitness

Dyspnea during light daily activities used as indicator of exercise intolerance and low fitness

Dyspnea, a sensation of breathlessness, during light daily activities can be used as an indicator of exercise intolerance and low fitness. According to a study on Finnish twins, persistent or developing dyspnea reveals an increased risk of death. [More]
Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013. [More]
Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure. [More]
EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer. [More]
Cycle test reliable for dyspnea evaluation in obese COPD patients

Cycle test reliable for dyspnea evaluation in obese COPD patients

Dyspnea in obese individuals with chronic obstructive pulmonary disease can be evaluated reliably by cycle ergometry as well as a treadmill test, researchers have found. [More]
Cetuximab fails in second-line combination for recurrent NSCLC

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy. [More]
Detectable blood viral load increases prevalence of heart disease

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load. [More]